CHMP backs approval of basket of drugs

On Friday, EMA's CHMP recommended approval of a host of therapies, including Rydapt midostaurin to treat acute myelogenous leukemia (AML), and Verkazia ciclosporin to treat severe vernal keratoconjunctivitis, a rare eye allergy.

CHMP backed approval of Rydapt from Novartis AG (NYSE:NVS; SIX:NOVN) to treat AML in adults. In April, FDA approved the drug for the same indication. It is an inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135) and stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117) (see BioCentury Extra, April 28). ...